4320.T
The company operates in the software industry, providing software solutions primarily within the health care technology sector.
Business. 4320.T is a software company operating within the Technology sector, specifically focused on software development and services. The firm utilizes a subscription-based revenue model, aligning with industry standards for tracking metrics such as annual recurring revenue and net revenue retention. Detailed information regarding the company's operating segments, headquarters location, and specific primary listing exchange is not available in the provided data. Consequently, the business is described at the industry level without specific geographic or segmental breakdowns.
At a glance
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-06-25 · SE
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4320.T is a software company operating within the Technology sector, specifically focused on software development and services. The firm utilizes a subscription-based revenue model, aligning with industry standards for tracking metrics such as annual recurring revenue and net revenue retention. Detailed information regarding the company's operating segments, headquarters location, and specific primary listing exchange is not available in the provided data. Consequently, the business is described at the industry level without specific geographic or segmental breakdowns.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥4,732,751,000, which is significantly higher than its total liabilities of ¥4,441,438,000. The current ratio of 3.18 indicates a robust ability to meet short-term obligations. The price-to-book ratio of 3.31 and a price-to-tangible-book ratio of 3.31 suggest that the company is trading at a premium relative to its book value.
Profitability metrics show that the company is performing well compared to industry standards. The return on equity (ROE) of 18.76% and return on assets (ROA) of 12.22% are strong indicators of efficient use of equity and assets to generate profits. The operating margin, calculated as operating income divided by revenue, is 8.7%, which is in line with the industry's preferred metrics.
The company's revenue is concentrated in the health care technology segment, with no disclosed geographic breakdown. This concentration may pose a risk if the health care technology market experiences a downturn. The company does not report revenue by geographic regions, making it difficult to assess regional exposure.
The company's growth trajectory is positive, with a revenue of ¥15,831,137,000 and a net income of ¥1,557,816,000. The free cash flow of ¥1,384,053,000 indicates that the company is generating sufficient cash to fund operations and potentially invest in growth opportunities. The capital expenditure of -¥593,825,000 suggests that the company is not heavily investing in new assets, which may indicate a focus on maintaining existing operations.
The risk assessment indicates that the company has low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio of 0.18 suggests that the company is not heavily leveraged, reducing financial risk. The absence of dilution potential and the low risk of dilution further supports the company's stable financial position.
Recent events and filings do not show any significant changes in the company's financial or operational status. The last actual EPS was 98.85 JPY, and the last actual revenue was ¥15,831,140,000. These figures align with the company's reported financial performance, indicating consistent results.
- The company has a strong liquidity position with a current ratio of 3.18 and significant cash reserves.
- Profitability is robust, with ROE and ROA of 18.76% and 12.22%, respectively.
- The company is not heavily leveraged, with a debt-to-equity ratio of 0.18.
- Free cash flow of ¥1,384,053,000 supports potential growth and operational flexibility.
- The company's revenue is concentrated in the health care technology segment, which may pose a risk if the market experiences a downturn.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Forward curve
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 4320.T Market data — financials · 2026-05-26
- CE Holdings Co Ltd Market data — analyst estimates · 2026-05-26